BioCryst (BCRX) Pharmaceuticals announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025. The board has appointed Charlie Gayer, currently the company’s chief commercial officer, as the company’s next president, effective August 1, 2025, and next chief executive officer, effective January 1, 2026. Stonehouse will continue to serve on the board of directors and Gayer will join the company’s board, effective January 1, 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst Pharmaceuticals’ BCX9930 Study Termination: Implications for Investors
- BioCryst Appoints New CFO to Drive Growth
- BioCryst appoints Babar Ghias as CFO, head of corporate development
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst price target raised to $15 from $13 at BofA